March 19, 2018
Lipid-based nanobiomaterials as liposomes and lipid nanoparticles (LNPs) are the most widely used nanocarriers for drug delivery systems (DDSs). Extracellular vesicles (EVs) and exosomes are also expected to be applied as DDS nanocarriers. The performance of nanomedicines relies on their components such as lipids, targeting ligands, encapsulated DNA, encapsulated RNA, and drugs. Recently, the importance of the nanocarrier sizes smaller than 100 nm is attracting attention as a means to improve the nanomedicine performance. Microfluidics and lab-on-a chip technologies make it possible to produce size-controlled LNPs by a simple continuous flow process and to separate EVs from blood samples by using a surface marker, ligand or electric charge, or by making a mass or particle size discrimination. Here, we overview recent advances in microfluidic devices and techniques for liposomes, LNPs and EVs and their applications for DDSs.
Publication - Abstract
Aug 29, 2017
Journal of Liposome Research
Understanding the effect of liposome size on tendency for accumulation in tumor tissue requires preparation of defined populations of different sized particles. However, controlling the size distributions without changing the lipid composition is d...
Publication - Abstract
Nov 30, 2018
Nanoscale Advances